CJC-1295 + Ipamorelin BlendCJC-1295 + Ipamorelin Blend
A dual-secretagogue blend with uncertain formulation and no robust clinical evidence for the marketed combination.
Answer a short online consultation. A clinician reviews it, and you only pay if treatment is approved. Dispensed by our licensed facility.
What it is
This product combines a GHRH-related peptide labelled CJC-1295 with the ghrelin-receptor agonist ipamorelin. The CJC component’s sequence, DAC status and individual quantities need confirmation.
The ingredients target different pituitary signalling pathways, providing a theoretical basis for a greater growth hormone response. A larger hormonal response is not necessarily a safer or more useful outcome.
Why people ask about it
People enquire about combining two pathways for sleep or body-composition goals, but online blend claims often omit formulation differences.
What the science says
Individual secretagogue studies cannot establish the performance of this exact blend. Controlled human trials demonstrating patient-centred benefits and long-term safety for marketed CJC-1295/ipamorelin mixtures are lacking.
Is it right for me?
Online consultation and clinician approval are needed before payment for the CJC/ipamorelin blend, including confirmation of both ingredients rather than assessment by brand name alone.
How Welcuren works
Complete a short online consultation about your health and goals.
A clinician reviews your answers, may ask follow-up questions, and decides whether this treatment is appropriate for you.
You only pay once treatment is approved. Our licensed facility then dispatches it with full instructions, on tracked global delivery.
Safety
Dual stimulation could increase endocrine adverse effects, including fluid retention and altered glucose handling, with additional uncertainty if DAC is present. Diabetes, active cancer, pituitary disease, pregnancy and breastfeeding need review; your clinician will advise
Questions
Does every CJC/ipamorelin blend contain DAC?
No; a blend name does not establish whether the CJC ingredient includes the albumin-binding component.
Do two receptors guarantee better results?
Biological plausibility does not demonstrate superior clinical outcomes.
Can the total blend mass identify each component?
Individual quantities require explicit composition information rather than inference from total mass.
Why are glucose results relevant to this blend?
Growth hormone-axis activation can affect insulin sensitivity, making metabolic history important.
This information is educational and not a substitute for advice from your clinician. Prescription treatments are only supplied after a clinical consultation.
Often considered together
Many clients start with a blood test so their clinician has a full picture.
AOD-9604 5mgAOD-9604 5mg
AOD-9604 5mg is supplied in a branded pre-filled pen with case, available only following an online consultation and clinician approval.
CJC-1295 No DAC 5mgCJC-1295 No DAC 5mg
A label commonly used for modified GRF(1–29), distinct from the albumin-binding CJC-1295 studied in published trials.
CJC-1295 with DAC 2mgCJC-1295 with DAC 2mg
An albumin-binding GHRH analogue studied in small human trials for hormonal responses, not proven wellness outcomes.